Results: 5

2.
Figure 2

Figure 2. From: A Long-Term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia among 20,000 Women in the Portland Kaiser Cohort Study.

Type-specific HPV results at enrollment, and positive predictive value of worst disease observed in follow-up. Figure 2a. Women <30. Figure 2b. Women 30+.

Mark Schiffman, et al. Cancer Epidemiol Biomarkers Prev. ;20(7):1398-1409.
3.
Figure 4

Figure 4. From: A Long-Term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia among 20,000 Women in the Portland Kaiser Cohort Study.

Cumulative Probability of CIN2 Stratified by HPV Test Results. The curves exclude enrollment cases of cytologic HSIL or histologic ≥CIN2, to permit calculation of hazard ratios using proportional hazards methods. The percentages of excluded enrollment cases are plotted separately as plus signs in the first year time bin. The numbers of women still at risk for each HPV test stratum are listed below the graph. The cumulative risk (cumulative probability) is plotted using Kaplan-Meier methods that take into account censoring due to cytologic HSIL or histologic ≥CIN2 or losses to follow-up. The PPV includes all cases observed combining enrollment and follow-up, but does not take into account censoring. Figure 4a. Women <30: HPV16 infection, cumulative probability = 19.5 (95% CI = 14.2-26.3) and PPV = 14.7 (11.4-18.0); other carcinogenic types, cumulative probability = 14.1 (9.9-19.8), PPV= 7.8 (6.0-9.6); no carcinogenic types, cumulative probability = 4.1 (3.4-5.0) and PPV = 1.8 (1.5-2.2). Figure 4b. Women 30+: HPV16 infection, cumulative probability = 9.7 (95% CI = 2.7-31.4) and PPV = 15.9 (9.9-21.8); other carcinogenic types, cumulative probability = 10.1 (7.0-14.4), PPV= 10.4 (7.6-13.2); no carcinogenic types, cumulative probability = 1.3 (1.0-1.8) and PPV = 0.8 (0.6-0.9).

Mark Schiffman, et al. Cancer Epidemiol Biomarkers Prev. ;20(7):1398-1409.
4.
Figure 3

Figure 3. From: A Long-Term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia among 20,000 Women in the Portland Kaiser Cohort Study.

Cumulative Probability of ≥CIN3 Stratified by HPV Test Results. The curves exclude enrollment cases of cytologic HSIL or histologic ≥CIN2, to permit calculation of hazard ratios using proportional hazards methods. The percentages of excluded enrollment cases are plotted separately as plus signs in the first year time bin. The numbers of women still at risk for each HPV test stratum are listed below the graph. The cumulative risk (cumulative probability) is plotted using Kaplan-Meier methods that take into account censoring due to cytologic HSIL or histologic ≥CIN2 or losses to follow-up. The PPV includes all cases observed combining enrollment and follow-up, but does not take into account censoring. Figure 3a. Women <30: HPV16 infection, cumulative probability = 14.6 (95% CI = 10.0-20.9) and PPV = 11.1 (8.1-14.0); other carcinogenic types, cumulative probability = 7.0 (4.2-11.4), PPV= 3.2 (2.0-4.3); no carcinogenic types, cumulative probability = 1.8 (1.2-2.5) and PPV = 0.7 (0.4-0.9). Figure 3b. Women 30+: HPV16 infection, cumulative probability = 8.5 (95% CI = 4.1-17.2) and PPV = 13.8 (8.2-19.4); other carcinogenic types, cumulative probability = 3.1 (1.6-6.1) and PPV= 3.7 (2.0-5.4); no carcinogenic types, cumulative probability = 0.7 (0.5-0.9) and PPV = 0.4 (0.3-0.5).

Mark Schiffman, et al. Cancer Epidemiol Biomarkers Prev. ;20(7):1398-1409.
5.
Figure 5

Figure 5. From: A Long-Term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia among 20,000 Women in the Portland Kaiser Cohort Study.

Cumulative Probability of ≥CIN2 Stratified by HPV Test and Cytology Results. The curves exclude enrollment cases of ≥CIN2, to permit calculation of hazard ratios using proportional hazards methods. The percentages of excluded enrollment cases are plotted separately as plus signs in the first year time bin. The numbers of women still at risk for each HPV test stratum are listed below the graph. The cumulative probability is plotted using Kaplan-Meier methods that take into account censoring due to cytologic HSIL or histologic ≥CIN2 or losses to follow-up. The PPV includes all cases observed combining enrollment and follow-up, but do not take into account censoring. Figure 5a. Women <30: HPV+ ASC/LSIL, cumulative probability = 8.9 (95% CI = 5.2-15.0) and PPV = 14.9 (11.1-18.6); HPV- ASC/LSIL, cumulative probability = 6.4 (2.2-17.7), AR= 5.8 (2.1-9.5); HPV+ NILM, cumulative probability = 15.2 (11.7-19.6) and PPV = 7.2 (5.5-8.8), HPV- NILM, cumulative probability = 3.9 (3.1-4.9) and AR = 1.6 (1.3-1.9). Figure 5b. Women 30+: HPV+ ASC/LSIL, cumulative probability = 7.4 (95% CI = 3.4-15.8) and PPV = 24.2 (16.5-31.8); HPV- ASC/LSIL, cumulative probability = 1.4 (0.5-3.7), PPV= 2.3 (0.8-3.8); HPV+ NILM, cumulative probability = 8.9 (5.9-13.5) and PPV = 6.1 (3.9-8.3), HPV- NILM, cumulative probability = 1.1 (0.9-1.4) and PPV = 0.7 (0.5-0.8).

Mark Schiffman, et al. Cancer Epidemiol Biomarkers Prev. ;20(7):1398-1409.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk